Kornitzer Capital Management Inc. KS Grows Holdings in ICON Public Limited (NASDAQ:ICLR)

Kornitzer Capital Management Inc. KS boosted its stake in ICON Public Limited (NASDAQ:ICLR - Free Report) by 50.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 74,820 shares of the medical research company's stock after acquiring an additional 25,160 shares during the period. Kornitzer Capital Management Inc. KS owned 0.09% of ICON Public worth $21,179,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Groesbeck Investment Management Corp NJ boosted its holdings in shares of ICON Public by 15.3% during the 4th quarter. Groesbeck Investment Management Corp NJ now owns 2,186 shares of the medical research company's stock valued at $619,000 after buying an additional 290 shares in the last quarter. Cullen Investment Group LTD. bought a new stake in shares of ICON Public during the 4th quarter valued at $1,620,000. Pinnacle Bancorp Inc. boosted its holdings in shares of ICON Public by 110.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 105 shares of the medical research company's stock valued at $30,000 after buying an additional 55 shares in the last quarter. Prime Capital Investment Advisors LLC bought a new stake in shares of ICON Public during the 4th quarter valued at $416,000. Finally, Sara Bay Financial boosted its holdings in shares of ICON Public by 6.3% during the 4th quarter. Sara Bay Financial now owns 2,766 shares of the medical research company's stock valued at $783,000 after buying an additional 163 shares in the last quarter. Institutional investors own 95.61% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently commented on ICLR. Evercore ISI boosted their target price on shares of ICON Public from $325.00 to $350.00 and gave the company an "outperform" rating in a report on Friday, February 23rd. Robert W. Baird lifted their price target on ICON Public from $345.00 to $362.00 and gave the stock an "outperform" rating in a research report on Thursday, April 4th. Barclays lifted their price target on ICON Public from $325.00 to $355.00 and gave the stock an "overweight" rating in a research report on Friday, February 23rd. Mizuho reaffirmed a "buy" rating and issued a $346.00 price target on shares of ICON Public in a research report on Thursday, April 4th. Finally, Truist Financial lifted their price target on ICON Public from $357.00 to $367.00 and gave the stock a "buy" rating in a research report on Friday, February 23rd. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $319.45.

ICON Public Stock Performance

NASDAQ:ICLR traded down $3.59 during mid-day trading on Friday, reaching $288.23. The company's stock had a trading volume of 647,943 shares, compared to its average volume of 415,333. ICON Public Limited has a 12-month low of $181.92 and a 12-month high of $344.77. The firm's fifty day moving average price is $316.95 and its two-hundred day moving average price is $281.13. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 0.40. The stock has a market cap of $23.78 billion, a P/E ratio of 39.06, a PEG ratio of 1.36 and a beta of 1.15.

ICON Public (NASDAQ:ICLR - Get Free Report) last issued its earnings results on Wednesday, February 21st. The medical research company reported $3.40 earnings per share for the quarter, topping analysts' consensus estimates of $3.27 by $0.13. ICON Public had a return on equity of 11.42% and a net margin of 7.54%. The business had revenue of $2.07 billion during the quarter, compared to analyst estimates of $2.08 billion. On average, equities analysts forecast that ICON Public Limited will post 14.4 EPS for the current fiscal year.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.